I disagree with all of your post.
Most of this is an insane take. If we were paying $5M pre-results - yes you would have a point. But this is $230k. It is a critical component of using iPSC derived MSCs to treat wounds. Without it, we either develop our own (how much do you think that would cost?), or pay a royalty per bandage (how much do you think that would cost?), or just simply avoid the wound space. Given it's worth 10-11 figures per annum, USD, that would be an outrageous decision, given the positive pre-clinical data.
student curiousity and credit should have been enough for them
Oh ok, can you please tell me how you pay for groceries using student curiousity? Do you have to walk up to the checkout aisle (assuming there are any open) and convince the clerk of your intellect to take home the roast chook?
which means we are giving those holding the IP in it a windfall - are they entitled to a windfall?
$230k is not a windfall. I don't think you'll find anyone on your side about that.
Most of your post speaks of someone who feels very strongly about shareholder rights, but doesn't properly understand how to run a business.
Shareholder activism only works when you understand why levers are being pulled and what other levers are available to you. Without purchasing this IP, CYP-006 becomes far more difficult to license as there is now another party that needs to be dealt with, and that ONLY complicates things.
(20min delay)